4-(5-(((7-phenylquinazolin-4-yl)amino)methyl)pyridin-2-yl)thiomorpholine 1,1-dioxide | 1384181-43-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-(5-(((7-phenylquinazolin-4-yl)amino)methyl)pyridin-2-yl)thiomorpholine 1,1-dioxide
• 英文别名: N-[[6-(1,1-dioxo-1,4-thiazinan-4-yl)pyridin-3-yl]methyl]-7-phenylquinazolin-4-amine
• CAS: 1384181-43-4
• 化学式: C₂₄H₂₃N₅O₂S
• 分子量: 445.545
• InChiKey: FXEJXNYTTCVMHA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  96.5
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• Compound as WNT Signaling Inhibitor, Composition, and Use Thereof
  申请人：An Songzhou

  公开号：US20150119387A1

  公开（公告）日：2015-04-30

  The present invention relates to a compound having the structure of Formula I as inhibitor of WNT signal transduction pathways, as well as a composition comprising the compound. Further, the present invention relates to the use of the compound and the method of inhibiting the WNT signal transduction pathways.

  本发明涉及一种具有Formula I结构的化合物作为WNT信号传导途径的抑制剂，以及包含该化合物的组合物。此外，本发明涉及该化合物的使用以及抑制WNT信号传导途径的方法。
• Compounds for Treatment of Cancer
  申请人：CUREGENIX, INC.

  公开号：US20160000780A1

  公开（公告）日：2016-01-07

  The present invention relates to compounds as inhibitor of WNT signal transduction pathway, as well as a composition comprising the same. Further, the present invention relates to the use of the compounds in the treatment of cancer.

  本发明涉及作为WNT信号转导途径抑制剂的化合物，以及包含该化合物的组合物。此外，本发明涉及使用该化合物治疗癌症。
• Compounds for Treatment of Fibrosis Diseases
  申请人：CUREGENIX, INC.

  公开号：US20160000779A1

  公开（公告）日：2016-01-07

  The present invention relates to compounds as inhibitor of WNT signal transduction pathway, as well as a composition comprising the same. Further, the present invention relates to the use of the compounds in the treatment of fibrosis. Fibrosis is the formation of excess fibrous connective tissue in an organ or tissue in a reparative or reactive process. Fibrosis is the end result of chronic inflammatory reactions induced by a variety of stimuli including persistent infections, autoimmune reactions, allergic responses, chemical insults, radiation, and tissue injury.

  本发明涉及作为WNT信号转导途径抑制剂的化合物，以及包含该化合物的组合物。此外，本发明还涉及将该化合物用于纤维化的治疗。纤维化是在器官或组织中形成过多的纤维结缔组织的修复或反应性过程。纤维化是由多种刺激引起的慢性炎症反应的最终结果，包括持续感染、自身免疫反应、过敏反应、化学物质损伤、辐射和组织损伤。
• Compound as WNT signaling inhibitor, composition, and use thereof
  申请人：CUREGENIX, INC.

  公开号：US10087181B2

  公开（公告）日：2018-10-02

  The present invention related to a compound having the structure of Formula I as inhibitor of WNT signal transduction pathways, as well as a composition comprising the compound. Further, the present invention relates to the use of the compound and the method of inhibiting the WNT signal transduction pathways.

  本发明涉及一种具有式 I 结构的作为 WNT 信号转导通路抑制剂的化合物，以及包含该化合物的组合物。此外，本发明还涉及该化合物的用途和抑制 WNT 信号转导途径的方法。
• Compounds for treatment of cancer
  申请人：Curegenix, Inc.

  公开号：US10238652B2

  公开（公告）日：2019-03-26

  The present invention relates to compounds as inhibitor of WNT signal transduction pathway, as well as a composition comprising the same. Further, the present invention relates to the use of the compounds in the treatment of cancer.

  本发明涉及作为 WNT 信号转导通路抑制剂的化合物，以及包含这些化合物的组合物。此外，本发明还涉及这些化合物在治疗癌症中的用途。